Amendments To The Claims

The listing of claims presented below will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. **(currently amended)** A compound ~~**of riboflavin derivatives selected from the group consisting of**~~ **which is** 5'-lauric acid ~~**monester of riboflavin, isobutyrate of riboflavin, riboflavin-2,6-dimethoxybenzoate, and adamantane acid**~~ ester of riboflavin.

2- 5 (canceled)

6. **(currently amended)** An oil suspension preparation ~~**using the compound of claim 1**~~ comprising as a main active constituent being mainly composed of ethyl oleate and the compound of ~~**claim 1 in**~~ Formula II:



Formula II.

7. **(currently amended)** The suspension preparation according to claim 6, wherein camellia oil is added and the ratio of weight and volume of each ingredient are as follows:

Compound **of Formula** II 50 - 150 mg,

Ethyl oleate	0.1 - 1 ml, **and**
Camellia oil	0-1 ml.

8. **(currently amended)** The suspension preparation according to claim 7, wherein the preferable ratio of weight and volume of each ingredient are as follows:

Compound of Formula II	150 mg,
Ethyl oleate	0.5 ml, **and**
Camellia oil	0.5 ml.

9-11. (canceled)

12. (previously presented) A method of ~~using~~ **therapeutically treating either an ariboflavinosis condition, a digestive tract catarrh, or a persistent oral ulcer of an animal** ~~a compound of claim 1,~~ comprising **the steps of:** ~~using a~~ **obtaining a suspension** preparation containing ~~the compound to treat a disease~~ **a main active constituent being mainly composed of ethyl oleate and the compound of Formula II:**



Formula II; and

administering a portion of the suspension preparation to the animal.

13-20. (canceled)

21. (new) The method of claim 12 further comprising the step of: subjecting the animal to a chemotherapy regimen.

22. (new) The method of claim 21 wherein the chemotherapy regimen is selected from the group consisting of high-dose methotrexate (HDMTX) chemotherapy, and DA (daunorubicin, cytosine arabinoside) chemotherapy.

22. (new) The method of claim 12 wherein the administering step comprises injecting the portion of the suspension preparation into the animal.

23. (new) The method of claim 12 wherein the administering step comprises injecting intermuscularly the portion of the suspension preparation into the animal.

24. (new) The method of claim 12 wherein the administering step comprises feeding the portion of the suspension preparation to the animal.

25. (new) The method of claim 12, wherein the suspension preparation is used to treat the ariboflavinosis condition.

26. (new) The method of claim 12, wherein the suspension preparation is used to treat digestive tract catarrh caused by bone marrow transplantation, leukemia or chemotherapy.

27. (new) The method of claim 12, wherein the suspension preparation is used to treat persistent oral ulcer.

28. (new) The method of claim 12, wherein the animal is a rat.

29. (new) The method of claim 12, wherein the animal is a human.

30. (new) The method of claim 12, wherein the suspension preparation further contains camellia oil.

31. (new) The method of claim 29, wherein the suspension preparation is combined with relative ranges of weights and volumes of each ingredient as follows:

Compound of Formula II	**50 - 150 mg;**
Ethyl oleate	**0.1 - 1 ml; and**
Camellia oil	**0-1 ml.**

32. (new) The method of using the compound of claim 31, wherein the suspension preparation is combined with relative ranges of weights and volumes of each ingredient as follows:

Compound of Formula II	**150 mg,**
Ethyl oleate	**0.5 ml, and**
Camellia oil	**0.5 ml.**